Inhibidores BET. El singular compuesto (+)-JQ1

  1. María del Carmen Avendaño López
Revista:
Anales de la Real Academia Nacional de Farmacia

ISSN: 1697-4298 0034-0618

Año de publicación: 2015

Volumen: 81

Número: 3

Páginas: 214-220

Tipo: Artículo

Otras publicaciones en: Anales de la Real Academia Nacional de Farmacia

Resumen

The serendipitous discovery of (bromodomain extra-terminal) (BET) inhibitors, especially of the BRD4 bromodomain inhibitors, has allowed modulation of gene transcription with epigenetic drugs. This is the case of protooncogen c- MY C and other genes involved in carcinogenesis and different disfunctions. These drugs, that include the compound (+)-JQ1, have shown their potencial as anticancer agents, immunomodulators, male contraceptives, antiviral, or heart failure chemopreventive agents, among others. In this review we analyze their discovery, structure, mechanism of action and future perspectives.